Shopping Cart
- Remove All
- Your shopping cart is currently empty
YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1]. |
In vitro | YIAD-0205, at concentrations of 10 and 100 μM, inhibits the aggregation of Aβ (1-42) [1]. |
In vivo | YIAD-0205 (50 mg/kg; oral administration; biweekly for one month) was effective in reducing levels of Aβ plaques and Aβ oligomers in the 5XFAD mouse model aged at 6.0 months [1]. |
Molecular Weight | 565.69 |
Formula | C26H16Br2ClN3 |
Cas No. | 2446054-34-6 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.